IMAGING

The partnership seeks to contribute to driving healthcare transformation across Saudi Arabia, aligning with the Kingdom's 'Saudi Vision 2030' strategy.

Techsomed's BioTrace platform, currently in advanced clinical evaluation, is a significant advancement in Image Guided Ablation Therapy. The technology leverages standard imaging—such as ultrasound (US) along with computed tomography (CT) or magnetic resonance imaging (MRI).

Jie Xue, President and CEO of MR at GE HealthCare. “Our latest PET/MR technology will directly impact the most challenging diseases, such as prostate cancer and Alzheimer's Disease. These diseases require precise and comprehensive imaging for accurate diagnosis, treatment planning, and therapy monitoring. We are excited to see SIGNA PET/MR AIR addressing these challenges and fulfilling our vision of providing access to advanced, personalized care.”

“Combining our expertise in noninvasive monitoring and signal processing technologies with Philips’ expertise in integrated patient monitoring and therapy solutions is a win-win for patients and clinicians alike," said Jon Coleman, President of Worldwide OEM Sales and Global Health, Masimo. "We are proud that Philips has chosen to make our innovative SedLine, O3, and NomoLine technologies available to their customers. We look forward to continuing our partnership with a focus on improving patient outcomes and reducing the cost of care.”

The Lumicell DVS is an investigational system designed for use in patients with breast cancer to assist in the detection of residual cancerous tissue within the lumpectomy cavity following removal of the primary specimen during breast conserving surgery.

Philips CT 3500, is a new high-throughput CT system targeting the needs of routine radiology and high-volume screening programs. Powered by AI, the Philips CT 3500 includes a range of image-reconstruction and workflow-enhancing features that help to deliver the consistency, speed, and first-time-right image quality needed for confident diagnoses by clinicians and increased return on investment – even in the most demanding, high-volume care settings. 

The results were presented today at the European Association of Percutaneous Cardiovascular Interventions (EuroPCR) 2023 course and will also be presented later this week at the Society for Cardiovascular Angiography & Interventions (SCAI) 2023 scientific sessions.

Olympus advises the EVIS X1 endoscopy system recently received FDA 510(k) clearance along with two compatible gastrointestinal endoscopes: the GIF-1100 gastrointestinal videoscope indicated for use within the upper digestive tract and the CF-HQ1100DL/I colonovideoscope indicated for use within the lower digestive tract, which will also be displayed.